Clinical Trials Logo

Clinical Trial Summary

Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes. It is often necessary to supplement the diet of patients with nutritional formulas. The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.


Clinical Trial Description

Main objective: • To compare the digestive tolerance of an oligomeric nutritional supplement with respect to a polymeric nutritional supplement in a group of patients diagnosed with anorexia nervosa under follow-up by the Nutrition Unit. Secondary Objectives: - Assess the gastrointestinal tolerance of the oral nutritional supplement on a single occasion with respect to a continuous intake over a period of 4 weeks. - Evaluate the impact of oral nutritional supplementation on nutritional status over a four-week period. - Evaluate the impact of oral nutritional supplementation on the functional capacity of the patient in a period of four weeks. - Evaluate the impact of oral nutritional supplementation on the patient's body composition over a four-week period. - Evaluate the impact of oral nutritional supplementation on the quality of life of the patient in a period of four weeks. - Evaluate the impact of oral nutritional supplementation on the depressive and anxious symptoms of the patient in a period of four weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05184738
Study type Interventional
Source Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Contact Ignacio Ruiz García, MD, PhD
Phone 951290343/951030117
Email [email protected]
Status Recruiting
Phase N/A
Start date October 15, 2021
Completion date May 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Recruiting NCT04213820 - TMS and Body Image Treatment for Anorexia Nervosa N/A
Recruiting NCT03414112 - The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa Early Phase 1
Not yet recruiting NCT04804800 - Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa N/A
Not yet recruiting NCT03600610 - Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa N/A
Recruiting NCT02962726 - Microbiome Shifts in Adolescent Anorexia Nervosa N/A
Enrolling by invitation NCT02745067 - Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa N/A
Completed NCT02382055 - Changing Habits in Anorexia Nervosa: Novel Treatment Development N/A
Terminated NCT02240797 - Kappa Opioid Receptor Imaging in Anorexia N/A
Completed NCT03075371 - Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa N/A
Completed NCT03144986 - Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa N/A
Unknown status NCT01761942 - Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Phase 2
Completed NCT02551445 - A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders. N/A
Completed NCT01579682 - Adaptive Family Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT00946816 - The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity N/A
Recruiting NCT00942929 - Lung Function Tests in Adolescents With Anorexia Nervosa N/A
Active, not recruiting NCT00759772 - The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa Phase 2
Completed NCT00271921 - Does Metabolic Syndrome Exist in Anorexia Nervosa? N/A
Completed NCT00184301 - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder. N/A
Completed NCT00260962 - Olanzapine in the Treatment of Patients With Anorexia Nervosa Phase 2